Increased sensitivity to cisplatin treatment was also observed in MDA-MB-231 breast cancer cells by knocking out the PHD finger protein 8 (PHF8) gene [59], suggesting that cisplatin resistance has multigenic character, with new genes been validated as potential targets for treatment-refractory cancers. Here, PHF8 is linked to cancer.